← SynDRA
LONAFARNIB
SynDRA canonical compound SYN0002623 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | FNTA |
|---|
| Mechanism of action | Farnesyltransferase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Farnesyltransferase inhibitor
- FNTA INHIBITOR
- Protein farnesyltransferase inhibitor
- FNTB INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- KSYK
- NSD2
- RASH
- RASK
- RASN
- SYK
Drug classes
- Enzyme Inhibitors
- Cytochrome P450 2C19 Inhibitors
- P-Glycoprotein Inhibitors
- Cytochrome P450 2C8 Inhibitors
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inhibitors
- Farnesyltransferase Inhibitor
- Farnesyltransferase Inhibitors
ATC classes
- A16A · OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Cross-references
Synonyms
- ZOKINVY
- Zokinvy
- zokinvy
- SCH 66336
- SCH66336
- Sarasar
- SCH-66336
- Lonafarnib [USAN]
- Sch-66336
- Sch66336
- SCH-066336
- Lonafarnib (USAN/INN)
- CHEMBL298734
- IOW153004F
- SMR004701448
- Lonafarnib [USAN:INN]
- Lonafarnib (SCH66336)
- lonafarnibum
- UNII-IOW153004F
- 1o5m
- LONAFARNIB [MI]
- LONAFARNIB [INN]
- (non-labelled)Lonafarnib-d9
- LONAFARNIB [WHO-DD]
- SCHEMBL19032
- MLS006010423
- MLS006011106
- GTPL8024
- LONAFARNIB [ORANGE BOOK]
- Lonafarnib, >=98% (HPLC)
- BDBM14459
- CHEBI:47097
- DTXSID90172927
- BCP07027
- EX-A1630
- ZINC3950115
- NSC719467
- s2797
Reported adverse events
- Abdominal pain
- Constipation
- Cough
- Dehydration
- Depressed mood
- Epistaxis
- Flatulence
- Headache
- Musculoskeletal pain
- Nausea
- Pruritus
- Rash
Look up LONAFARNIB in the interactive SynDRA portal →